Malcisbo AG

Malcisbo develops and commercializes innovative vaccines for animals based on carbohydrates.

Our focus is on bacterial diseases targeting animal health, human food safety and zoonotic diseases.

We offer sustainable solutions representing alternatives to antibiotics. Our vision is to be the leading provider of carbohydrate-based vaccines in veterinary medicine.

Our first product against Campylobacter is currently co-developed with a major vaccine company. Other products e.g. against pneumonia caused by Actinobacillus p.p. are also ongoing.

With investments up to EUR 10 Mio we will be able to develop multiple vaccines based on the same technology of presenting disease-specific carbohydrates on the surface of vaccine bacteria.